Endo : When a buck is a buck
https://www.cabot.net/News/2011/04/ENDP.aspx
Endo Pharma Partners with India R&D
Maura Lockwood, Cabot Headline News
April 18, 2011
Endo Pharmaceuticals (ENDP) is partnering with R&D firms in India to access researchers’ efforts there without having to invest in costly U.S.-based R&D infrastructure, Investor’s Business Daily reported.
Before 2009, Endo mainly focused on drugs to treat pain. To shift to a broader product line, the company acquired a series of companies to diversify its businesses, and now, the Indian partnerships will allow it to continue its expansion, IBD reported.
The Chadds Ford, Pennsylvania-based company’s Indian partnerships are with companies that have dedicated laboratories, allowing Endo to acquire the same intellectual output as in the U.S. but at one-quarter of the price, according to IBD.
Endo spends approximately $10 million a year on 15 drug-discovery programs based in India, as well as engaging in partnerships there with medical device companies, reported IBD. Endo Pharmaceuticals (ENDP) is a Cabot Top Ten Trader stock.